Alan Chait1, Ira Goldberg2. 1. Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA. achait@uw.edu. 2. Division of Endocrinology, New York University, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: This article reviews current knowledge concerning diabetic dyslipidemia and cardiovascular disease (CVD). It reviews strategies to reduce diabetes-associated CVD, including reducing low-density lipoprotein levels, lowering triglycerides, and increasing high-density lipoproteins (HDL). Special considerations, such as the multifactorial chylomicronemia syndrome and partial lipodystrophy, and the role of glucose-lowering strategies in the management of diabetic dyslipidemia are discussed. RECENT FINDINGS: The strongest evidence to date for reducing CVD in diabetes comes from the use of statins. While triglyceride lowering remains inconclusive, an ongoing trial might provide some finality to this question. The role of increasing HDL remains elusive, and HDL cholesterol appears to be an unsatisfactory metric for monitoring therapy. The use of statins offers the best current way to reduce diabetes-associated CVD. However, several novel and promising approaches for the management of diabetic dyslipidemia aimed at reducing CVD are in the pipeline.
PURPOSE OF REVIEW: This article reviews current knowledge concerning diabetic dyslipidemia and cardiovascular disease (CVD). It reviews strategies to reduce diabetes-associated CVD, including reducing low-density lipoprotein levels, lowering triglycerides, and increasing high-density lipoproteins (HDL). Special considerations, such as the multifactorial chylomicronemia syndrome and partial lipodystrophy, and the role of glucose-lowering strategies in the management of diabetic dyslipidemia are discussed. RECENT FINDINGS: The strongest evidence to date for reducing CVD in diabetes comes from the use of statins. While triglyceride lowering remains inconclusive, an ongoing trial might provide some finality to this question. The role of increasing HDL remains elusive, and HDL cholesterol appears to be an unsatisfactory metric for monitoring therapy. The use of statins offers the best current way to reduce diabetes-associated CVD. However, several novel and promising approaches for the management of diabetic dyslipidemia aimed at reducing CVD are in the pipeline.
Authors: Claude Gagné; Harold E Bays; Stuart R Weiss; Pedro Mata; Katherine Quinto; Michael Melino; Meehyung Cho; Thomas A Musliner; Barry Gumbiner Journal: Am J Cardiol Date: 2002-11-15 Impact factor: 2.778
Authors: W Virgil Brown; Luther Clark; James M Falko; John R Guyton; Tomas J Rees; Gustav Schonfeld; Maria F Lopes-Virella Journal: J Clin Lipidol Date: 2008-08-22 Impact factor: 4.766
Authors: K Hermansen; T A Bækdal; M Düring; A Pietraszek; L S Mortensen; H Jørgensen; A Flint Journal: Diabetes Obes Metab Date: 2013-06-11 Impact factor: 6.577
Authors: Erland Erdmann; John A Dormandy; Bernard Charbonnel; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene Journal: J Am Coll Cardiol Date: 2007-04-16 Impact factor: 24.094
Authors: Michel Farnier; Peter Jones; Randall Severance; Maurizio Averna; Elisabeth Steinhagen-Thiessen; Helen M Colhoun; Yunling Du; Corinne Hanotin; Stephen Donahue Journal: Atherosclerosis Date: 2015-11-14 Impact factor: 5.162
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Jenny E Kanter; Farah Kramer; Shelley Barnhart; Jeffrey M Duggan; Masami Shimizu-Albergine; Vishal Kothari; Alan Chait; Stephan D Bouman; Jessica A Hamerman; Bo F Hansen; Grith S Olsen; Karin E Bornfeldt Journal: Diabetes Date: 2018-02-26 Impact factor: 9.461
Authors: Isabela Silva Levindo de Siqueira; Rafael Alves Guimarães; Samira Nascimento Mamed; Thays Angélica de Pinho Santos; Suiany Dias Rocha; Valéria Pagotto; Karlla Antonieta Amorim Caetano; Claci Fátima Weirich Rosso Journal: Int J Environ Res Public Health Date: 2020-09-07 Impact factor: 3.390